|
Health insurance Innovations, Inc.
February 21, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Health Insurance Innovations, Inc. (“Health Insurance Innovations”, “HIIQ” or the “Company”) (NASDAQ: HIIQ), a company that purportedly distributes individual and family health insurance plans, including short-term medical insurance plans, and guaranteed-issue and underwritten health benefit insurance plans. Investors who purchased Health Insurance Innovations securities between February 28, 2018 and November 27, 2018, inclusive (the “Class Period”), may be affected. A complaint has been filed in the United States District Court for Middle District of Florida against the Company and certain executives (the “Action”).
|
|
Synergy Pharmaceuticals Inc.
February 20, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Synergy Pharmaceuticals Inc. (“Synergy” or the “Company”) (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of therapies to treat Gastro-Intestinal disorders and diseases. Investors who purchased Synergy securities between September 7, 2017 and October 25, 2018, inclusive (the “Class Period”), may be affected. A complaint has been filed in the United States District Court for the Eastern District of New York against certain Synergy executives.
|
|
CPI Aerostructures Inc.
February 19, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of CPI Aerostructures Inc. (NYSE: CVU).
|
|
Mattel, Inc.
February 19, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Mattel, Inc. (Nasdaq: MAT). Purchasers of Mattel securities between February 8 and 15, 2019 may be affected.
|
|
Uxin Limited
February 14, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Uxin Limited (“Uxin” or the “Company”) (NASDAQ: UXIN), a Chinese company that operates an e-commerce platform for buying and selling cars. A complaint has been filed in the United States District Court for the Eastern District of New York against the Company, certain executives and the underwriters of Uxin’s June 2018 initial public offering (“IPO”) on behalf of investors who purchased or otherwise acquired Uxin’s publicly traded securities pursuant to and/or traceable to the Company’s IPO.
|
|
Bristow Group Inc.
February 14, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Bristow Group Inc. (NYSE: BRS).
|
|
Astec Industries, Inc.
February 14, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Astec Industries, Inc. (“Astec” or the “Company”) (NASDAQ: ASTE). Investors who purchased Astec stock between July 26, 2016 and October 22, 2018, inclusive (the “Class Period”), may be affected. A complaint has been filed in the United States District Court for the Eastern District of Tennessee against Astec, its Chief Executive Officer and its Chief Financial Officer on behalf of investors of Astec stock during the Class Period.
|
|
Arlo Technologies, Inc.
February 11, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Arlo Technologies, Inc. (“Arlo” or the “Company”) (NYSE: ARLO), a company that provides smart connected devices, such as security cameras. A complaint has been filed against the Company and certain executives in the United States District Court for the Northern District of California on behalf of investors who purchased Arlo common stock pursuant or traceable to Arlo’s August 2018 initial public offering (the “IPO”).
|
|
Helius Medical Technologies, Inc.
February 7, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Helius Medical Technologiues, Inc. (“Helius” or the “Company”) (Nasdaq: HSDT).
|
|
Cavco Industries, Inc.
February 7, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Cavco Industries, Inc. (“Cavco” or the “Company”) (Nasdaq: CVCO).
|
|
Corcept Therapeutics Incorporated
February 5, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ : CORT).
|
|
Wirecard AG
February 1, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Wirecard AG (“Wirecard” or the “Company”) (OTC: WCAGY, WRCDF), an online payment processing company based in Europe, concerning potential securities law violations. Investors who purchased Wirecard securities may be affected.
|
|
22nd Century Group, Inc.
January 28, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of 22nd Century Group, Inc. (“22nd Century” or the “Company”) (NYSE American: XXII). Investors who purchased 22nd Century securities between February 18, 2016 and October 25, 2018, inclusive (the “Class Period”), may be affected. A complaint has been filed in the United States District Court for the Eastern District of New York on behalf of investors of 22nd Century securities during the Class Period.
|
|
Ferroglobe PLC
January 28, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Ferroglobe PLC (“Ferroglobe” or the “Company”) (NASDAQ: GSM), purportedly one of the world’s largest producers of silicon metal, silicon-based alloys and manganese-based alloys. Investors who purchased Ferroglobe securities between August 21, 2018 and November 26, 2018, inclusive (the “Class Period”), may be affected.
|
|
Amdocs Limited
January 23, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Amdocs Limited (“Amdocs” or the “Company”) (Nasdaq: DOX).
|
|
YRC Worldwide Inc.
January 24, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of YRC Worldwide Inc. (“YRC” or the “Company”) (NASDAQ: YRCW), a company that provides various transportation services primarily in North America. Investors who purchased or otherwise acquired YRC securities between March 10, 2014 and December 14, 2018, inclusive (the “Class Period”), may be affected. A complaint has been filed in the United States District Court for the Northern District of New York against YRC and certain executives on behalf of investors in YRC securities during the Class Period.
|
|
Snap, Inc.
January 16, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Snap, Inc. (“Snap” or the “Company”) (NYSE: SNAP). Investors who purchased Snap common stock between March 2, 2017 and August 10, 2017, inclusive (the “Class Period”) may be affected.
|
|
Danske Bank A/S
January 24, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Danske Bank A/S American Depository Shares (“Danske” or the “Company”) (OTC: DNKEY) (CUSIP: 236363206).
|
|
GreenSky, Inc.
January 15, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of GreenSky, Inc. (“GreenSky” or the “Company”) (NASDAQ: GSKY). GreenSky is a financial technology company that runs an online platform for processing loan applications at the point of sale.
|
|
AxoGen, Inc.
January 11, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN), a company that purports to provide surgical solutions for physical damage or discontinuity to peripheral nerves. AxoGen’s products include nerve allografts and extracellular matrices. Investors who purchased AxoGen securities between August 7, 2017 and December 18, 2018, inclusive (the “Class Period”) may be affected.
|
|
Alkermes plc
January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or the “Company”) (NASDAQ: ALKS). Investors who purchased Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the “Class Period”) may be affected. A complaint has been filed in the United States District Court for the Eastern District of New York against Alkermes, the Company’s Chairman and CEO, and its CFO on behalf of investors of Alkermes securities during the Class Period.
|
|
Immunomedics Inc.
January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU). Investors who purchased Immunomedics common stock between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”) may be affected. A complaint has been filed in the United States District Court for the District of New Jersey against Immunomedics, the Company’s President and CEO, and its CFO on behalf of investors in Immunomedics common stock during the Class Period.
|
|
DXC Technology Company
January 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of DXC Technology Company (“DXC Technology” or the “Company”) (NYSE: DXC). Investors who purchased DXC Technology common stock between February 8, 2018 and November 6, 2018, inclusive (the “Class Period”) may be affected. A complaint has been filed in the United States District Court for the Eastern District of Virginia against DXC Technology, J. Michael Lawrie, the Company’s CEO, and Paul N. Saleh, the Company’s CFO, on behalf of investors in DXC Technology common stock during the Class Period.
|
|
Perrigo Company plc
January 2, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Perrigo Company plc (“Perrigo”) (NYSE: PRGO) securities. Perrigo is a global healthcare company that is headquartered in Ireland, and sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.
|
|
Nobilis Health Corp.
December 17, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Nobilis Health Corp. (“Nobilis”) (NYSE American: HLTH) securities between May 8, 2018 and November 15, 2018 (the “Class Period”). A complaint has been filed in the United States District Court for the Southern District of Texas against Nobilis, the Company’s CEO, and its former and current CFOs on behalf of investors of Nobilis securities during the Class Period.
|
|
Belden Inc.
December 13, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Belden Inc. securities (“Belden” or the “Company”) (NYSE: BDC).
|
|
Cheetah Mobile Inc.
December 7, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Cheetah Mobile Inc. (“Cheetah” or the “Company”) (NYSE: CMCM). Investors who purchased Cheetah securities between April 26, 2017 and November 27, 2018 (the “Class Period”) may be affected. A complaint has been filed in the United States District Court for the Southern District of New York against Cheetah, the Company’s CEO, and its CFO on behalf of investors of Cheetah securities during the Class Period.
|
|
Aphria Inc.
December 4, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Aphria Inc. (“Aphria” or the “Company”) (NYSE: APHA) concerning potential securities law violations. Investors who purchased Aphria securities may be affected.
|
|
Marriott International, Inc.
November 30, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Marriott International, Inc. (“Marriott” or the “Company”) (NASDAQ: MAR) concerning potential securities law violations. Investors who purchased Marriott securities may be affected.
|
|
Goldman Sachs Group, Inc.
November 14, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Goldman Sachs Group, Inc. (“Goldman Sachs” or the “Company”) (NYSE: GS) concerning potential securities law violations. Investors who purchased Goldman Sachs securities may be affected.
|
